FAFazal Abbas

Fazal Abbas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fazal Abbas has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Bushra Nawaz

    Department of Electronics Engineering, University of Engineering and Technology 5 , Taxila 47080, Pakistan

    1 shared publication
  • Bushra Nawaz

    Department of Electronics Engineering, University of Engineering and Technology Taxila, Taxila 47080, Pakistan

    1 shared publication
  • Ghulam Ali

    U.S.‐Pakistan Center for Advanced Studies in Energy (USPCASE) National University of Sciences and Technology (NUST) Islamabad Pakistan

    1 shared publication
  • Ishaq Ahmad

    National Center for Physics, Quaid-i-Azam University, Islamabad 44000, Pakistan

    1 shared publication
  • Javed Iqbal

    Department of Physics, Quaid-i-Azam University 2 , Islamabad 44000, Pakistan

    1 shared publication
  • M. S. Haider Naqvi

    Department of Biochemistry, University of Karachi 7 , Karachi 74000, Pakistan

    1 shared publication

Latest Publications

  • Open Access

    Investigation of the Electrochemical Properties of Ni0.5Zn0.5Fe2O4 as Binder-Based and Binder-Free Electrodes of Supercapacitors

    by Bushra Nawaz, Ghulam Ali, Muhammad Obaid Ullah, Sarish Rehman, Fazal Abbas

    In this work, Ni0.5Zn0.5Fe2O4 is synthesized as binder-based (NZF) and binder-free electrodes (NZF@NF). The binder-free electrode is directly synthesized on nickel foam via facile hydrothermal techniques. The crystalline phase of both of these electrodes is examined through X-ray diffraction. Their morphology is investigated by scanning electron microscopy (SEM) and high-resolution transmission electron microscopy (TEM), which revealed the well-defined nanostructure with the shape like thin hexagonal platelets. The chemical composition is verified by energy dispersive spectroscopy (EDS). Their electrochemical properties are analyzed by cyclic voltammetry (CV), galvanostatic charge–discharge (GCD), and electrochemical impedance spectroscopy (EIS). The NZF@NF electrode has outperformed the binder-based NZF electrode in terms of electrochemical performance owing to the 3D interconnected structure of the nickel foam. The NZF@NF electrode has delivered a high specific capacity of 504 F g−1 at the current density of 1 A g−1, while its counterpart has delivered a specific capacity of 151 F g−1 at the same current density.


  • Open Access

    ROS mediated malignancy cure performance of morphological, optical, and electrically tuned Sn doped CeO2 nanostructures

    by Fazal Abbas, Javed Iqbal, Qaisar Maqbool, Tariq Jan, Muhammad Obaid Ullah, Bushra Nawaz, Mudassar Nazar, M. S. Haider Naqvi, Ishaq Ahmad

    To grapple with cancer, implementation of differentially cytotoxic nanomedicines have gained prime attention of the researchers across the globe. Now, ceria (CeO2) at nanoscale has emerged as a cut out therapeutic agent for malignancy treatment. Keeping this in view, we have fabricated SnxCe1-xO2 nanostructures by facile, eco-friendly, and biocompatible hydrothermal method. Structural examinations via XRD and FT-IR spectroscopy have revealed single phase cubic-fluorite morphology while SEM analysis has depicted particle size ranging 30-50nm for pristine and doped nanostructures. UV-Vis spectroscopy investigation explored that Sn doping significantly tuned the band gap (eV) energies of SnxCe1-xO2 nanostructures which set up the base for tremendous cellular reactive oxygen species (ROS) generations involved in cancer cells’ death. To observe cytotoxicity, synthesized nanostructures were found selectively more toxic to neuroblastoma cell lines as compared to HEK-293 healthy cells. This study anticipates that SnxCe1-xO2 nanostructures, in future, might be used as nanomedicine for safer cancer therapy.